NeuroRx
  • Home
  • About Us
  • Covid-19
  • NRX-100/101
  • News
  • Contact
  • Home
  • News
  • Broadcasts

Category: Broadcasts

Broadcasts

New COVID-19 drug used to treat patients suffering from respiratory failure is in trials

Fox Business Apr. 07, 2021 – 5:06 – NeuroRX CEO Dr. Jonathan Javitt discusses the new COVID-19 drug for respiratory distress and vaccine boosters.

Read more
Broadcasts

FDA Investigating Quality Issues That Led To Millions Of J&J Vaccines To Be Thrown Out

Cheddar News – Apr 2, 2021 02:23 pm

Read more
Broadcasts

New COVID 19 Drug can Effectively Treat Patients – Discussion with Dr. Javitt, CEO NeuroRx

Interview with Dr. Yo – Streamed live on Feb 11, 2021

Read more
Broadcasts

Prof Jonathan Javitt joins i24NEWS – FDA Grants Continuation of COVID-19 Trial

https://www.youtube.com/watch?v=ogvdYGj5hQQ&feature=share&fbclid=IwAR33RM6pud-jcg0K5WGpDzFq27PdTcu8rYKZ_VDQagylTubUFm7aIo1UWm4
Read more
Broadcasts

Focusing on You: UM Tests Drug to Lessen Severity of COVID-19

University of Miami Health System

Read more
Broadcasts

UM Hospital Testing New Treatment For Patients Suffering The Worst Of COVID-19

https://www.youtube.com/watch?v=ztSFZlavXU0&feature=youtu.be
Read more
Broadcasts

FDA advances Covid-19 therapy-Prof. Jonathan Javitt

https://www.youtube.com/watch?v=lgmpS2N8124
Read more

Categories

  • Broadcasts
  • News
  • Press releases

Tags

Accelerated Recovery ARDS Aviptadil BARDA Big Rock Partners Bipolar Depression Cheddar News Clinical Trials Covid-19 Critical COVID-19 Dr Yo Emergency Use Expanded Access Fast Track FDA FDA Emergency Use Authorization Fox Business GILD Gilead High Flow Nasal Houston I-Spy i24 News NASDAQ NIAID NIH NRX-100/101 NRXP Orphan Drug Designation Peptides Respiratory Failure RLF-100 RLF-100_002 Sar-CoV-2 Sever COVID-19 TESICO UCI Veklury VIP Virology ZYESAMI Zysami

Developing innovative therapies for high-mortality unmet needs.

Company Info

  • About Us
  • RLF-100
  • NRX 100/101

Learn More

  • USA-Licensed Physicians
  • Investors
© 2021 NeuroRx, Inc.